Monograph Details
|
|
Endocrine System
> Thyroid disease
|
|
TRIOSTAT |
| Manufacturer |
|
JHP Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
T3 (synthetic). |
| Generic Name |
|
Liothyronine (as sodium) 10micrograms/mL; soln for IV inj. |
| Indications |
|
Myxedema coma/precoma. |
| Children |
|
Not recommended. |
| Adults |
|
Give with glucocorticoids. Allow 4–12 hours between doses. Initially 25–50micrograms. Cardiovascular disease: initially 10–20micrograms. Usual range: 65–100micrograms daily. Change to oral therapy as soon as possible: start tabs at low dose and increase gradually; discontinue IV gradually. |
| Contraindications |
|
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis. Artificial rewarming. |
| Precautions |
|
Not for treatment of obesity. Cardiovascular disease, angina, elderly: initiate therapy at 10–20micrograms. Severe and prolonged hypothyroidism. Fluid therapy. Adrenocortical insufficiency. Pregnancy (Cat.A). Nursing mothers. |
| Interactions |
|
Potentiates digitalis toxicity, tricyclic antidepressants, sympathomimetics (e.g., anorectics). May increase risk of coronary insufficiency with vasopressors. Monitor oral anticoagulants, hypoglycemics. Estrogens affect thyroid function tests. May be potentiated by tricyclic antidepressants. Hypertension, tachycardia with ketamine. |
| Adverse Reactions |
|
Arrhythmia, tachycardia, cardiopulmonary arrest, hypotension, MI, angina, CHF, hypertension, twitching. |
| How Supplied |
|
Vials (1mL)—6 |
|
|
|
|
